A2A Pharma Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 9
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $3M
Latest Deal Amount
  • Investors
  • 3

A2A Pharma General Information

Description

Developer of a healthcare therapy intended to treat Leukemia, pancreatic and liver cancer. The company's therapy is useful to treat antibiotic-resistant bacterial infections and cancer and bacterial infections like Tuberculosis through its proprietary computational system, enabling healthcare professionals and physicians to treat their patients in an enhanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 180 Varick Street
  • New York, NY 10014
  • United States

A2A Pharma Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

A2A Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 06-Feb-2018 $3M 00.00 Completed Generating Revenue
3. Accelerator/Incubator 12-Dec-2017 00000 Completed Generating Revenue
2. Accelerator/Incubator 02-Nov-2016 $200K $200K 00.00 Completed Generating Revenue
1. Seed Round 01-Apr-2016 Completed Generating Revenue
To view A2A Pharma’s complete valuation and funding history, request access »

A2A Pharma Executive Team (7)

Name Title Board Seat Contact Info
Sotirios Stergiopoulos MD Co-Founder, President and Chief Executive Officer
Edward Painter Co-Founder, Chief Information Officer and Chairman
Chaemin Lim Ph.D Chief Scientific Officer
Sridhar Vempati Ph.D Co-Founder and Advisor
Matthew Welsch Ph.D Co-Founder and Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

A2A Pharma Board Members (3)

Name Representing Role Since
Andrew Dean Ph.D A2A Pharma Board Member 000 0000
Edward Painter A2A Pharma Co-Founder, Chief Information Officer and Chairman 000 0000
Matthew Welsch Ph.D A2A Pharma Co-Founder and Board Member 000 0000
To view A2A Pharma’s complete board members history, request access »

A2A Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

A2A Pharma Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
JLABS Accelerator/Incubator Minority 000 0000 000000 0
IndieBio Accelerator/Incubator Minority 000 0000 000000 0
SOSV Venture Capital Minority 000 0000 000000 0
To view A2A Pharma’s complete investors history, request access »

A2A Pharma Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000.00 19-Jul-2018 00000 0000000 Other Healthcare Technology Systems 00000 0000000 00.0
To view A2A Pharma’s complete investments history, request access »